French Big Pharma Sanofi-Aventis will soon begin selling its anti-obesity drug Acomplia.
A 20-mg per day version has been authorized for all 25 EU member states, with the first launch set for the UK in July.
Launches in Denmark, Ireland, Germany, Finland and Norway will occur by the end of this year.
But what of the biggest market?
Sanofi-Aventis hopes to receive full approval for Acomplia in the US by year-end. But they have never revealed what was in their FDA approvable letter though!
No comments:
Post a Comment